CML
Haematology · 2007–2026
12decisions
4medicines
3carried consumer input
5individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| asciminib Addition of nurse practitioners as eligible prescribers for continuing treatment phases of asciminib in patients with Ph+ CML (chronic phase or accelerated… | Mar 2026 | Recommended with restriction | no section in document |
| asciminib Treatment of patients 18 years of age and above with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP) previously… | Jul 2022 | Not recommended | input received Leukaemia Foundation · Leukemia Foundation · Rare Cancers Australia |
| asciminib Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase who have been previously treated with two or more… | Nov 2022 | Recommended with restriction | none received |
| ponatinib Chronic myeloid leukaemia (CML) in patients with T315I mutation who have failed prior tyrosine kinase inhibitor therapy, or in patients where both nilotinib… | Nov 2018 | Recommended | none received |
| dasatinib First-line treatment of patients with chronic myeloid leukaemia in the chronic phase. | Jul 2016 | Recommended with restriction | 3 individuals Haematology Society |
| ponatinib Treatment of adult patients with chronic myeloid leukaemia (CML) who have failed an adequate trial of dasatinib and nilotinib, or where one has failed and the… | Jul 2015 | Recommended with restriction | 2 individuals |
| dasatinib Amendment to first-line PBS restriction for chronic myeloid leukaemia (CML) to allow second and subsequent Authority required applications via telephone… | Jul 2014 | Not recommended | none received |
| Dasatinib treatment of newly diagnosed patients in the chronic phase of chronic myeloid leukaemia (CML) expressing the Philadelphia chromosome or the transcript, bcr-abl… | Jul 2011 | Recommended with restriction | unclear |
| nilotinib First-line treatment of chronic phase Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML-CP) | Jul 2011 | Recommended | unclear |
| nilotinib Treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukaemia (CML) in adult patients intolerant of, or resistant… | Mar 2008 | Recommended with restriction | no section in document |
| dasatinib Treatment of all phases of chronic myeloid leukaemia (CML) in adult patients expressing the Philadelphia chromosome or transcript, bcr-abl tyrosine kinase, who… | Mar 2007 | Recommended with restriction | no section in document |
| dasatinib Treatment of all phases of chronic myeloid leukaemia (CML) in adult patients expressing the Philadelphia chromosome or transcript bcr-abl tyrosine kinase, who… | Mar 2007 | Recommended with restriction | no section in document |
Who spoke
Leukaemia Foundation · Leukemia Foundation · Rare Cancers Australia · Haematology Society
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.